NCT01720602View on ClinicalTrials.gov

Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy

NACompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

March 31, 2015

Study Completion Date

January 31, 2020

Conditions

Male Breast CancerRecurrent Breast CancerStage IV Breast Cancer

Interventions

DRUG

vorinostat

Given PO

DRUG

anastrozole

Given PO

DRUG

letrozole

Given PO

DRUG

exemestane

Given PO

PROCEDURE

positron emission tomography

Correlative studies

RADIATION

F-18 16 alpha-fluoroestradiol

Correlative studies

RADIATION

fludeoxyglucose F 18

Correlative studies

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

98109

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

lead

University of Washington

OTHER

NCT01720602 - Vorinostat in Treating Patients With Stage IV Breast Cancer Receiving Hormone Therapy | Biotech Hunter | Biotech Hunter